Company
Pfizer
15 active trials that select patients by a biomarker on marked.bio, across 8 biomarkers; 5 in phase 3.
Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.
Biomarkers
Drugs in these trials
Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).
cetuximab 5lorlatinib 3encorafenib 3pembrolizumab 3binimetinib 2bevacizumab 2disitamab vedotin 2tucatinib 2fulvestrant 2claturafenib 2crizotinib 1trastuzumab 1letrozole 1
Upcoming readouts
Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.
- 2026-10 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Phase 3 · BRAF V600E
- 2027-10 A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Phase 1/2 · BRCA1/2 mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-)
Trials
15 of 69 trials shown
-
Lorlatinib Continuation Study
lorlatinib FDA EU
…CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORL…
ALK fusionROS1 fusionNon-Small-Cell Lung Cancer, NSCLC
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
PF-08046054docetaxel
Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following c…
EGFR exon 19 deletion / L858RALK fusionNon-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
encorafenib FDA EUbinimetinib FDA EUpembrolizumab
Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-…
BRAF V600EMelanoma
-
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
encorafenib FDA EUcetuximab FDA EUoxaliplatinirinotecanleucovorinfluorouracilcapecitabinebevacizumab
Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation
BRAF V600ENeoplasms
-
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
lorlatinib FDA EUcrizotinib FDA EU
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK-positive NSCLC
ALK fusionCarcinoma, Non-Small-Cell Lung
-
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
PF-08634404Chemotherapy
Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
EGFR exon 19 deletion / L858RSmall Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
-
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Known germline BRCA mutation must have received a PARP-inhibitor if available as local standard of care therapy and no…
BRCA1/2 mutationHER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer, Breast Neoplasms
-
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Cohort A (HER2-Low Breast Cancer) Inclusion Criteria
HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
-
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
encorafenib FDA EUcetuximab FDA EUpembrolizumab
Locally confirmed BRAF V600E mutation in tumor tissue or blood
BRAF V600EMSI-H / dMMRMetastatic Colorectal Cancer
-
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
tucatinibtrastuzumabfulvestrant
Known activating HER2 mutations detected in fresh or archival tumor tissue or blood
HER2 (ERBB2) activating mutationUterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
-
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
PF-08165784fulvestrant FDA EUAtirmociclibcetuximabletrozole
Phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutation
PIK3CA activating mutationAdvanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
PF-07934040gemcitabinenab-paclitaxelcetuximabfluorouraciloxaliplatinleucovorinbevacizumabpembrolizumabpemetrexedcisplatinpaclitaxel
Documentation of mutated KRAS gene
KRAS G12DCarcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
-
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
claturafenibbinimetinib FDA EUcetuximab FDA EUmidazolamfluorouracilleucovorinoxaliplatin
Part 3 (Cohort 4) (BRAF V600E CRC): Minimum of 2 cycles of prior 5-FU based chemotherapy required.
BRAF V600EMelanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
PF-07799544claturafenib
Evidence of a BRAF V600 mutation
BRAF V600EMelanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
-
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
lorlatinib FDA EU
…ologically confirmed diagnosis of locally advanced or metastatic (TNM 8th classification) ALK-positive NSCLC (IHC 3+/FISH positive/transcriptomic method)
ALK fusionALK+ Non-Small-Cell Lung Carcinoma
-
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
lorlatinib FDA EU
…cally confirmed diagnosis of unresectable advanced and/or recurrent NSCLC that carries an ALK rearrangement, as detected by an appropriate test.
ALK fusionAdvanced Non-Small Cell Lung Cancer
-
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
lorlatinib FDA EU
…static NSCLC (Stage IV, American Joint Committee on Cancer \[AJCC\] v7.0) that carries an ALK rearrangement.
ALK fusionCarcinoma, Non-Small-Cell Lung
-
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
encorafenib FDA EUbinimetinib FDA EUcetuximab FDA EUirinotecanleucovorinfluorouracil
Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening …
BRAF V600EBRAF V600E-mutant Metastatic Colorectal Cancer
-
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
dacomitinib FDA EUgefitinib FDA EU
…med, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21).
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer With EGFR-Activating Mutations
-
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
encorafenib FDA EUbinimetinib FDA EUvemurafenib FDA EU
…162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
BRAF V600EMelanoma
-
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
talazoparib FDA EUPhysician's-Choice
Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation from Myriad Genetics or other laboratory approved by the Sponsor
BRCA1/2 mutationBreast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
-
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
crizotinib FDA EUpemetrexedcisplatincarboplatin
Positive for translocation or inversion events involving the ALK gene locus.
ALK fusionNSCLC (Non-small Cell Lung Cancer)
-
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
treatment
Positive for translocation or inversion events involving the ALK gene locus
ALK fusionNon Squamous Lung Cancer
-
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
crizotinib FDA EUpemetrexeddocetaxel
positive for the ALK fusion gene (test provided by a central laboratory)
ALK fusionCarcinoma, Non-Small-Cell Lung
-
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
encorafenib FDA EUbinimetinib FDA EUpembrolizumabipilimumabnivolumab
Documented evidence of a BRAF V600E or V600K mutation.
BRAF V600EMelanoma
-
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
PF-06801591
EGFR mutation, BRAF mutation, and ALK or ROS1 translocation/rearrangement are not permitted
EGFR exon 19 deletion / L858RBRAF V600EAdvanced Malignancies, Non-small-cell Lung Cancer
-
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Sasanlimab Prefilled syringeencorafenib FDA EUbinimetinib FDA EUSasanlimabaxitinibSEA-TGT
BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or NGS assay a…
BRAF V600ECarcinoma, Non-Small-Cell Lung
-
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
encorafenib FDA EUbinimetinib FDA EU
Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local laboratory assay or the presence …
BRAF V600ENon-small Cell Lung Cancer
-
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
encorafenib FDA EUbinimetinib FDA EU
Presence of B-RAF proto-oncogene, V600 mutant (BRAFV600) mutation in tumor tissue previously determined by a local PCR or NGS-based assay at any …
BRAF V600EBrain Metastases
-
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
ladiratuzumab vedotinpembrolizumab
Must have received BRAF +/- MEK inhibitor therapy if BRAF mutated (Part C)
BRAF V600ESmall Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
-
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
lorlatinib FDA EU
… (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx).
ALK fusionCarcinoma, Non-Small-Cell Lung
-
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
avelumabbinimetinibtalazoparib
Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or oth…
KRAS G12CKRAS G12DPancreatic Cancer
-
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
talazoparib FDA EU
Germline BRCA 1/2 Mutation Positive
BRCA1/2 mutationEarly Breast Cancer
-
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
avelumabtalazoparib FDA EU
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
BRCA1/2 mutationLocally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
-
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
binimetinibnivolumabipilimumab
RAS mutation per local assay at any time prior to Screening or by the central laboratory.
KRAS G12CKRAS G12DMSS, RAS-mutant Colorectal Cancer
-
A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
talazoparib FDA EUtemozolomide
Have a deleterious germline or a somatic BRCA1 or BRCA2 mutation, or a high diagnostic HRD test score (myChoice score ≥ 42), which represents a loss of DN…
BRCA1/2 mutationOvarian Cancer
-
A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer
PF-06459988
…istological or cytologically confirmed diagnosis of locally advanced or metastatic EGFRm (del19 or L858R) NSCLC that is resistant to standard therapy.
EGFR exon 19 deletion / L858RAdvanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
-
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
PF-06747775palbociclibavelumab
…tologically or cytologically confirmed diagnosis of locally advanced or metastatic EGFRm (del 19 or L858R) NSCLC:
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
avelumabUtomilumabPF-04518600PD 0360324CMP-001
Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted.
EGFR exon 19 deletion / L858RAdvanced Cancer
-
Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
encorafenib FDA EU
Presence of BRAF V600E mutation in tumor tissue
BRAF V600ENon-Small Cell Lung Cancer
-
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
encorafenib FDA EUbinimetinib FDA EUribociclibinfigratinibbuparlisibcapmatinib
Documented evidence of BRAF V600 mutation.
BRAF V600EMelanoma
-
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
WNT974encorafenib FDA EUcetuximab FDA EU
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
BRAF V600EMetastatic Colorectal Cancer
-
LGX818 for Patients With BRAFV600 Mutated Tumors
encorafenib FDA EU
Patient's tumor has been evaluated and pre-identified as having a tumor with a BRAFV600 mutation at a CLIA certified laboratory.
BRAF V600ESolid Tumor, Hematologic Malignancies
-
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
crizotinib FDA EU
Positive for translocation or inversion events involving the ALK gene locus
ALK fusionNon-Small Cell Lung Cancer
-
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
lorlatinib FDA EUcrizotinib FDA EU
…tologically confirmed diagnosis of metastatic NSCLC (Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food and Drug Administration (FDA) approved FISH assay (Abbott Mole…
ALK fusionROS1 fusionALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
-
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
encorafenib FDA EU
confirmed BRAF V600 mutation
BRAF V600EMelanoma
-
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
ribociclibencorafenib FDA EU
Diagnosis of locally advanced or metastatic melanoma along with written documentation of BRAF V600 mutation.
BRAF V600ELocally Advanced Metastatic BRAF Mutant Melanoma
-
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
talazoparib FDA EU
Deleterious or pathogenic germline BRCA 1 or BRCA 2 mutation
BRCA1/2 mutationBreast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
-
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
crizotinib FDA EU
Positive for translocation or inversion events involving the ROS1 gene
ROS1 fusionNon Small Cell Lung Cancer, ROS1 Proto Oncogene, Crizotinib
-
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
encorafenib FDA EUbinimetinib FDA EUribociclib
Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation
BRAF V600ESolid Tumors Harboring a BRAF V600 Mutation
-
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
encorafenib FDA EUcetuximab FDA EUalpelisib
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
BRAF V600EColorectal Cancer
-
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
binimetinib FDA EUAMG 479
Patients with advanced solid tumors (CRC, melanoma) with documented somatic KRAS or BRAFV600 mutations in tumor tissue.
BRAF V600EMetastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
-
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
binimetinib FDA EU
…h Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations
BRAF V600EBRAF or NRAS Mutant Metastatic Melanoma
-
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
crizotinib FDA EU
positive for the ALK fusion gene (test provided by either a central laboratory.
ALK fusionCarcinoma, Non-Small-Cell Lung
-
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
PF-07985045gemcitabinenab-paclitaxelcetuximabfluorouraciloxaliplatinleucovorinbevacizumabpembrolizumabSasanlimabpemetrexedcisplatin
Documentation of mutated KRAS gene
KRAS G12CKRAS G12DCarcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
-
PF-07284892 in Participants With Advanced Solid Tumors
PF-07284892lorlatinibbinimetinibcetuximabencorafenib
…or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor.
KRAS G12CKRAS G12DBRAF V600EALK fusionSolid Tumor
-
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
PF-07284890binimetinib FDA EUmidazolam
Documented evidence of a BRAF V600 mutation in tumor tissue or blood
BRAF V600EMalignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
-
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
binimetinib FDA EUencorafenib FDA EU
…ion of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
BRAF V600EMelanoma
-
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
PF-07265807Sasanlimabaxitinib
Part 4, Cohort 1: Participants with NSCLC with METex14-skipping alteration(s) and progressed on at least 1 prior therapy.
MET exon 14 skippingNeoplasm Metastasis
-
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
PF-06946860
Pembrolizumab for MSI-H • Will be entering the study at the first or second cycle of their current course of anti…
MSI-H / dMMRCachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
-
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
losartandextromethorphancaffeineomeprazolemidazolamrosuvastatinbupropion immediate release (IR)encorafenib FDA EUbinimetinib FDA EUmodafinil
Presence of BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment, as determined using a local te…
BRAF V600EAdvanced Solid Tumors, Metastatic Melanoma
-
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
talazoparib FDA EU
Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation by Myriad Genetics' BRACAnalysis CDx test.
BRCA1/2 mutationNeoplasms, Breast Neoplasms
-
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
crizotinib FDA EUpembrolizumab
Alk-positive NSCLC as determined by a test that is approved or validated for use as a companion diagno…
ALK fusionALK-positive Advanced NSCLC
-
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
The patients' tumors must contain documented activating somatic BRAFV600E\* , NRAS or KRAS mutations (except for pancreatic cancer)
KRAS G12CKRAS G12DBRAF V600EAdvanced Solid Tumors
-
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
gedatolisibmirdametinibirinotecan
For patients enrolled in Stage 2 of Arm C, advanced colorectal cancer (both KRAS mutated and KRAS wild type), which has progressed on irinotecan-based regimens, and pancreatic du…
KRAS G12CKRAS G12DBRAF V600EAdvanced Cancer
-
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
encorafenib FDA EU
Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation.
BRAF V600EMelanoma and Metastatic Colorectal Cancer
-
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
talazoparib FDA EU
Breast and ovarian cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.
BRCA1/2 mutationAdvanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
-
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
crizotinib FDA EU
positive for translocation or inversion event involving the ALK gene locus
ALK fusionNeoplasms Malignant
-
Treatment Resistance Following Anti-cancer Therapies
germline mutated BRCA (gBRCAm), HER2- breast cancer: PD on a PARP inhibitor monotherapy in patients previously treated …
BRCA1/2 mutationDisease Progression
No trials match these filters.